Jennifer S. Haas, MD, MSPH

This study highlights the potential value of innovative ways of collecting information about adverse drug events directly from patients.

Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.